107 related articles for article (PubMed ID: 33246161)
21. Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study.
Duarte X; Esteves S; Neto AM; Pereira F
Br J Haematol; 2016 Jul; 174(2):280-91. PubMed ID: 27018199
[TBL] [Abstract][Full Text] [Related]
22. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
[TBL] [Abstract][Full Text] [Related]
23. Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI. Medical Research Council Working Party on Childhood Leukaemia.
Richards S; Burrett J; Hann I; Chessells J; Hill F; Bailey C
Leukemia; 1998 Jul; 12(7):1031-6. PubMed ID: 9665186
[TBL] [Abstract][Full Text] [Related]
24. Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002.
Karachunskiy A; Tallen G; Roumiantseva J; Lagoiko S; Chervova A; von Stackelberg A; Aleinikova O; Bydanov O; Bajdun L; Nasedkina T; Korepanova N; Kuznetsov S; Novichkova G; Goroshkova M; Litvinov D; Myakova N; Ponomareva N; Inyushkina E; Kondratchik K; Abugova J; Fechina L; Arakaev O; Karelin A; Lebedev V; Judina N; Scharapova G; Spichak I; Shamardina A; Ryskal O; Shapochnik A; Rumjanzew A; Boos J; Henze G;
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1001-1012. PubMed ID: 30840197
[TBL] [Abstract][Full Text] [Related]
25. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
26. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia.
Chessells JM; Bailey C; Richards SM
Lancet; 1995 Jan; 345(8943):143-8. PubMed ID: 7823668
[TBL] [Abstract][Full Text] [Related]
27. Prolonged
Mondelaers V; Suciu S; De Moerloose B; Ferster A; Mazingue F; Plat G; Yakouben K; Uyttebroeck A; Lutz P; Costa V; Sirvent N; Plouvier E; Munzer M; Poirée M; Minckes O; Millot F; Plantaz D; Maes P; Hoyoux C; Cavé H; Rohrlich P; Bertrand Y; Benoit Y;
Haematologica; 2017 Oct; 102(10):1727-1738. PubMed ID: 28751566
[TBL] [Abstract][Full Text] [Related]
28. Risk-directed therapy for childhood acute lymphoblastic leukemia. Results of the Associazione Italiana Ematologia Oncologia Pediatrica '82 studies.
Vecchi V; Aricò M; Basso G; Ceci A; Madon E; Mandelli F; Masera G; Massimo L; Pession A; Zanesco L
Cancer; 1993 Oct; 72(8):2517-24. PubMed ID: 8402470
[TBL] [Abstract][Full Text] [Related]
29. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
Badowska W
Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
[TBL] [Abstract][Full Text] [Related]
31. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
Welte K; Reiter A; Mempel K; Pfetsch M; Schwab G; Schrappe M; Riehm H
Blood; 1996 Apr; 87(8):3143-50. PubMed ID: 8605328
[TBL] [Abstract][Full Text] [Related]
32. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
[TBL] [Abstract][Full Text] [Related]
33. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.
Silverman LB; Gelber RD; Dalton VK; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Arkin S; Declerck L; Cohen HJ; Sallan SE
Blood; 2001 Mar; 97(5):1211-8. PubMed ID: 11222362
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.
Hough R; Rowntree C; Goulden N; Mitchell C; Moorman A; Wade R; Vora A
Br J Haematol; 2016 Feb; 172(3):439-51. PubMed ID: 26683485
[TBL] [Abstract][Full Text] [Related]
35. [Treatment results with ALL-BFM-95 protocol in children with acute lymphoblastic leukemia in Hungary].
Müller J; Kovács G; Jakab Z; Rényi I; Galántai I; Békési A; Kiss C; Nagy K; Kajtár P; Bartyik K; Masát P; Magyarosy E
Orv Hetil; 2005 Jan; 146(2):75-80. PubMed ID: 15724956
[TBL] [Abstract][Full Text] [Related]
36. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
37. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.
Aricò M; Valsecchi MG; Conter V; Rizzari C; Pession A; Messina C; Barisone E; Poggi V; De Rossi G; Locatelli F; Micalizzi MC; Basso G; Masera G
Blood; 2002 Jul; 100(2):420-6. PubMed ID: 12091331
[TBL] [Abstract][Full Text] [Related]
38. Impact of reduced chemotherapy treatment for good risk childhood acute lymphoblastic leukaemia on infectious morbidity*.
van Tilburg CM; Sanders EA; Nibbelke EE; Pieters R; Revesz T; Westers P; Wolfs TF; Bierings MB
Br J Haematol; 2011 Feb; 152(4):433-40. PubMed ID: 21223250
[TBL] [Abstract][Full Text] [Related]
39. [High risk acute lymphoblastic leukaemia in children. Preliminary report after introducing a new version of New York (1997) protocol adjusted to the age of the patients. Report of the Polish Paediatric Leukaemia/Lymphoma Study Group].
Skoczen S; Klus K; Armata J; Kowalczyk J; Wisniewska-Slusarz H; Kolecki P; Derwich K; Matysiak M; Krauze A; Rokicka-Milewska R; Pawelec K; Boguslawska-Jaworska J; Juszczak K; Pisarek J; Sońta-Jakimczyk D; Tomaszewska R; Łuszczynska A; Wysocki M; Styczyński J
Med Wieku Rozwoj; 2000; 4(1 Suppl 2):23-32. PubMed ID: 12021459
[TBL] [Abstract][Full Text] [Related]
40. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
Lange BJ; Bostrom BC; Cherlow JM; Sensel MG; La MK; Rackoff W; Heerema NA; Wimmer RS; Trigg ME; Sather HN;
Blood; 2002 Feb; 99(3):825-33. PubMed ID: 11806983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
